<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04238390</url>
  </required_header>
  <id_info>
    <org_study_id>UQCCR-DP-AS-2019-001</org_study_id>
    <nct_id>NCT04238390</nct_id>
  </id_info>
  <brief_title>Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection</brief_title>
  <acronym>MERINO III</acronym>
  <official_title>A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme (Australia) Pty Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Queensland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ceftolozane-tazobactam is as effective as
      meropenem with respect to 30 day mortality in the treatment of bloodstream infection due to
      third-generation cephalosporin non-susceptible Enterobacterales or a known chromosomal
      AmpC-producing Enterobacterales (Enterobacter spp., Citrobacter freundii, Morganella
      morganii, Providencia spp. or Serratia marcescens).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enterobacterales are common causes of bacteraemia, and may produce extended-spectrum
      beta-lactamases (ESBLs) or AmpC beta-lactamases. ESBL or AmpC producers are typically
      resistant to third generation cephalosporins such as ceftriaxone, but susceptible to
      carbapenems. In no study has the outcome of treatment for serious infections for ESBL
      producers been significantly surpassed by carbapenems. Despite the potential advantages of
      carbapenems for treatment of ceftriaxone non-susceptible organisms, widespread use of
      carbapenems may cause selection pressure leading to carbapenem-resistant organisms. This is a
      significant issue since carbapenem-resistant organisms are treated with last-line antibiotics
      such as colistin.

      Ceftolozane-tazobactam is a combination of a new beta-lactam antibiotic with an existing
      beta-lactamase inhibitor, tazobactam, and is active against ESBL and most AmpC producing
      organisms. In a large sample of ESBL- and AmpC-producing Enterobacterales isolates from
      urinary tract and intra-abdominal specimens, ceftolozane-tazobactam was susceptible in over
      80%. It has been FDA approved for complicated urinary tract infections (cUTI) and complicated
      intra-abdominal infections (cIAI), and more recently for hospital-acquired and
      ventilator-associated pneumonia (HAP/VAP). In addition, a pooled analysis of phase 3 clinical
      trials has shown favourable clinical cure rates with ceftolozane-tazobactam for cUTI and cIAI
      caused by ESBL-producing Enterobacterales. Given the issues of carbapenem resistant
      organisms, there is a need for establishing the efficacy of an alternative to carbapenems for
      serious infections.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality rate at 30 days</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare the 30-day mortality from day of randomisation of each regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality rate at 14 days</measure>
    <time_frame>14 days post randomisation</time_frame>
    <description>To compare the 14-day mortality from day of randomisation of each regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and microbiological success</measure>
    <time_frame>5 days post randomisation</time_frame>
    <description>Defined as survival PLUS resolution of fever (temperature &lt;38 degrees Celsius) PLUS improved SOFA score (as compared to baseline) PLUS sterilisation of blood cultures at Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional bacteraemia score (FBS)</measure>
    <time_frame>0 and 30 days post randomisation</time_frame>
    <description>To compare the functional bacteraemia score of patients treated with each regimen at baseline and Day 30 (scored 0-7, higher scores equal better outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological relapse</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare the rates of relapse of bloodstream infection (microbiological failure) with each regimen at Day 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of new bloodstream infection</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare the rates of new bloodstream infection (growth of a new organism from blood cultures - not a contaminant as determined by treating clinician) with each regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of in-patient hospital and ICU stay</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare lengths of in-patient hospital and ICU stay with each regimen (not including in-patient rehabilitation, long term acute care or hospital in the home)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events</measure>
    <time_frame>Day 1 to last dose plus 24 hours of treatment:</time_frame>
    <description>To compare the number of treatment emergent serious adverse events with each regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridioides difficile infection</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare rates of Clostridioides difficile infection with each regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonisation and/or infection with multi-resistant bacterial organisms</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare rates of colonisation and/or infection with multi-resistant bacterial organisms (MROs) including those newly acquired</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desirability of Outcome Ranking (DOOR) with partial credit</measure>
    <time_frame>30 days post randomisation</time_frame>
    <description>To compare the Desirability of Outcome Ranking (DOOR) with partial credit with each regimen (scored 0-100, higher scores equal better outcomes)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">630</enrollment>
  <condition>Bacteremia Caused by Gram-Negative Bacteria</condition>
  <arm_group>
    <arm_group_label>Ceftolozane-tazobactam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Meropenem</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ceftolozane-Tazobactam</intervention_name>
    <description>Ceftolozane-tazobactam 3 grams (comprising ceftolozane 2 grams and tazobactam 1 gram) administered, every 8 hours, three times a day, intravenously over 60 mins. Dose adjusted for renal function.</description>
    <arm_group_label>Ceftolozane-tazobactam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meropenem</intervention_name>
    <description>Meropenem 1 gram, every 8 hours, three times a day, intravenously over 30 mins. Dose adjusted for renal function.</description>
    <arm_group_label>Meropenem</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bloodstream infection defined as presence in at least one peripheral blood culture
             draw demonstrating Enterobacterales with proven non-susceptibility to third generation
             cephalosporins or cephalosporin susceptible species known to harbour chromosomal
             AmpC-beta-lactamases (Enterobacter spp., Klebsiella aerogenes, Citrobacter freundii,
             Morganella morganii, Providencia spp. or Serratia marcescens) during hospitalisation

          -  Patient is aged 18 years and over (21 and over in Singapore)

          -  The patient or approved proxy is able to provide informed consent

          -  ≤72 hours has elapsed since the first positive qualifying (index) blood culture
             collection

          -  Expected to receive IV therapy for ≥5 days

        Exclusion Criteria:

          -  Known hypersensitivity to a cephalosporin or a carbapenem, or anaphylaxis to
             beta-lactam antibiotics

          -  Participant with significant polymicrobial bloodstream infection (i.e. not a
             contaminant)

          -  Treatment is not with the intent to cure the infection (i.e. palliative intent) or the
             expected survival is ≤4 days

          -  Participant is pregnant or breast-feeding (tested for in women of child-bearing age
             only)

          -  Use of concomitant antimicrobials with known activity against Gram-negative bacilli
             (except trimethoprim/sulfamethoxazole for Pneumocystis prophylaxis and when adding
             metronidazole for suspected IAI) in the first 5 days post-randomisation

          -  Participant with CrCl &lt;15 mL/minute or on renal replacement therapy (in addition,
             participants will be withdrawn from the study if CrCl reaches this level)

          -  Previously randomised in the MERINO-3 trial or concurrently enrolled in another
             therapeutic antibiotic clinical trial

          -  Blood culture isolate with in-vitro resistance to either meropenem or
             ceftolozane-tazobactam (known either at time of enrolment or during the course of
             study treatment, in which case the participant will be withdrawn)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adam G Stewart, MBBS</last_name>
    <phone>+61733465555</phone>
    <email>merino3@uq.edu.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roberta Littleford, PhD</last_name>
    <phone>+61733465555</phone>
    <email>merino3@uq.edu.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>John Iredell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woolongong Hospital</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Spyrion Miyakis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Adam G Stewart</last_name>
    </contact>
    <investigator>
      <last_name>David L Paterson, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrew Henderson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Monica Slavin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Anton Peleg</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Rogers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dandenong Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3175</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Benjamin Rogers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Ingram</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Matthew Skinner</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Ingram</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Maddelena Giannella</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Biomediche e Cliniche</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabio Franzetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università di Pisa</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Marco Falcone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Matteo Bassetti</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sanremo Hospital</name>
      <address>
        <city>Sanremo</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Chiara Dentone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Fahad Specialist Hospital</name>
      <address>
        <city>Dammam</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <contact>
      <last_name>Reem Almagrabi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Medical City - Jeddah</name>
      <address>
        <city>Jeddah</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <contact>
      <last_name>Asim Alsaedy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>King Abdulaziz Medical City</name>
      <address>
        <city>Riyadh</city>
        <zip>14611</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <contact>
      <last_name>Thamer Alenazi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>Paul Tambyah</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>Shirin Kalimuddin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <contact>
      <last_name>David Lye</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bellvitge University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Miguel Pujol</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alex Soriano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Juan Horcajada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Nativida Benito</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mutua Terrassa University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Esther Calbo</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Italy</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>January 19, 2020</last_update_submitted>
  <last_update_submitted_qc>January 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Ceftolozane</mesh_term>
    <mesh_term>Ceftolozane, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

